---
title: "3 High-Risk, High-Reward Stocks to Buy Now for Explosive Upside, According to Analysts – 5/8/2026"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285782545.md"
description: "Analysts highlight three high-risk, high-reward stocks for potential explosive gains: Inventiva (IVA), Pharming Group (PHAR), and Atai Life Sciences (ATAI). Inventiva is focused on lanifibranor, a promising drug for treating nonalcoholic steatohepatitis (NASH), with early Phase III trial data showing positive results. The stock has a Strong Buy consensus rating, and the average price target suggests a 193.3% upside from its current price of $15.75. Investors are encouraged to consider these stocks for significant market opportunities."
datetime: "2026-05-08T22:44:37.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285782545.md)
  - [en](https://longbridge.com/en/news/285782545.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285782545.md)
---

# 3 High-Risk, High-Reward Stocks to Buy Now for Explosive Upside, According to Analysts – 5/8/2026

High-risk, high-reward stocks are for investors looking for stocks that can offer dramatic upside in the market. Analysts are pointing to several small-cap names that could deliver strong gains if their clinical or commercial catalysts play out. Three stocks, including Inventiva (IVA), Pharming Group (PHAR), and Atai Life Sciences (ATAI), stand out for their breakthrough pipelines and upcoming milestones.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

## **1\. Inventiva (IVA)**

Inventiva is developing lanifibranor, one of the most closely watched drug candidates in the race to treat nonalcoholic steatohepatitis (NASH), a multibillion-dollar market with limited approved therapies. The company has significant upside potential if the drug is approved. Importantly, early data from the drug's Phase III trial show improvements in fibrosis and liver function.

Turning to Wall Street, IVA stock has a Strong Buy consensus rating based on nine Buys assigned in the last three months. At $15.75, the average Inventiva stock price target implies upside potential of 193.3%.

### Related Stocks

- [IVA.US](https://longbridge.com/en/quote/IVA.US.md)
- [PHAR.US](https://longbridge.com/en/quote/PHAR.US.md)
- [ATAI.US](https://longbridge.com/en/quote/ATAI.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)

## Related News & Research

- [Assessing Inventiva (ENXTPA:IVA) Valuation After Recent Share Price Volatility](https://longbridge.com/en/news/286962960.md)
- [Assessing AtaiBeckley (ATAI) Valuation After First Quarter Loss And Improved Per Share Results](https://longbridge.com/en/news/286882302.md)
- [Relay drug shows early promise against rare blood vessel diseases](https://longbridge.com/en/news/287094432.md)
- [NeOnc Advances Glioma Programs and Strengthens Financial Position](https://longbridge.com/en/news/286826865.md)
- [20:03 ETHarbour BioMed Announces Promising Preclinical Data for LET003, Its First AI-Enabled Drug Candidate](https://longbridge.com/en/news/286688082.md)